Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Rev. med. Chile ; 150(8): 1046-1053, ago. 2022. tab
Article in Spanish | LILACS | ID: biblio-1431873

ABSTRACT

BACKGROUND: Both perfectionism and social anxiety have been described in patients with eating disorders (ED) and medical students. Academic stress also can increase the risk of developing ED. AIM: To analyze the dimensions of perfectionism, social anxiety, and academic stress associated with the risk of developing ED in female medical students. MATERIAL AND METHODS: The Multidimensional Perfectionism Scale, the Liebowitz Social Anxiety Scale, the SISCO academic stress inventory and the Eating Attitudes Test-26, were applied to 163 female medical students from all levels of the career. The groups with and without risk of ED were compared according to these variables. Results: Twenty-four percent of respondents were at risk of ED. There were significant differences between scores of perfectionism, social anxiety, and academic stress between respondents with and without risk for ED. In general, there was a significant correlation among the variables. In a multivariate analysis, the predictors of ED risk were the perception of academic stress (Odds ratio (OR) 1.09; 95% confidence intervals (CI) 1.03-1.16) and personal standards in the context of perfectionism (OR 1.16; 95% CI 1.06-1.27). CONCLUSIONS: A substantial proportion of female medical students were at risk for ED. The risk of ED was determined mainly by academic stress and personal standards in the context of perfectionism. In this sample, social anxiety did not play a relevant role.


Subject(s)
Humans , Female , Students, Medical , Feeding and Eating Disorders , Perfectionism , Anxiety
2.
Medwave ; 21(6): e8315, jul. 2021.
Article in English, Spanish | LILACS | ID: biblio-1284255

ABSTRACT

Este artículo forma parte de una serie metodológica colaborativa de revisiones narrativas sobre bioestadística y epidemiología clínica. El objetivo de este trabajo es presentar conceptos básicos respecto de las revisiones sistemáticas de intervenciones múltiples con metanálisis en red. Para las preguntas clínicas en las que hay muchas alternativas terapéuticas que compiten (o se comparan) entre sí. La pregunta central es cómo clasificar u ordenar jerárquicamente su efecto (beneficio y/o daño) para escoger la mejor opción. Los metanálisis en red buscan responder a preguntas relacionadas con la efectividad o seguridad de múltiples tratamientos comparados entre sí, mediante el análisis simultáneo de resultados surgidos tanto de comparaciones directas como de comparaciones indirectas. La geometría de la red (network geometry) es la representación gráfica general de los metanálisis en red y permite comprender e incluso evaluar la fuerza de las comparaciones. Para que un metanálisis de comparaciones múltiples sea válido debe cumplir una serie de supuestos, destacándose el supuesto de transitividad que permite asumir que no hay diferencias sistemáticas entre las comparaciones disponibles, a excepción de las intervenciones comparadas. Así, es posible conocer la efectividad terapéutica relativa entre cualquier par de intervenciones del metanálisis en red y el orden de las intervenciones en términos de su categorización. Se ha propuesto utilizar el modelo Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) modificado en cuanto a las particularidades de los metanálisis en red para valorar la certeza de la evidencia, tanto para cada comparación como para la jerarquización de intervenciones.


This article belongs to a collaborative methodological series of narrative reviews about biostatistics and clinical epidemiology. The goal is to present basics concepts concerning the systematics reviews of multiple treatments comparisons with network meta-analysis. For clinical ques-tions with several therapeutic alternatives to be compared, the central question is how to classify or rank their effectiveness (benefit and harm) to choose the best option. The network meta-analysis aims to answer questions related to the effectiveness and safety of comparing multiple treatments by the simultaneous analysis of results raised from direct and indirect comparisons. The network geometry is the general graphical representation of the network meta-analysis and allows to understand and assess the strength of comparisons. The network meta-analysis should check several assumptions to be valid, especially the transitivity assumption, which allows assuming that there are no systematic differences among the included comparisons, except their compared interventions. Thus, it is possible to know the relative therapeutic effectiveness of each pair of interventions included in the network meta-analysis and their ranking in terms of categorization. It has been proposed to use a modified Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach considering the distinctive features of network meta-analysis to assess the certainty of the evidence for each comparison and the ranking of interventions.


Subject(s)
Humans , Network Meta-Analysis , Systematic Reviews as Topic , Decision Making
3.
Medwave ; 20(11)dic. 2020.
Article in English | LILACS | ID: biblio-1146034

ABSTRACT

OBJETIVO Proporcionar un resumen oportuno, riguroso y continuamente actualizado de la evidencia disponible sobre el papel de los macrólidos para el tratamiento de pacientes con COVID-19. DIDEÑO Revisión Sistemática Viva. BASE DE DATOS: La búsqueda de evidencia se realizó en el repositorio centralizado L·OVE (Living OVerview of Evidence) COVID-19; una plataforma que mapea las preguntas PICO para identificar la evidencia en la base de datos Epistemonikos. En respuesta a la emergencia de COVID-19, L·OVE se adaptó para ampliar el rango de evidencia que cubre y hoy se mantiene a través de búsquedas regulares en 39 bases de datos. MÉTODOS: Se incluyeron estudios experimentales que evaluaban el efecto de los macrólidos, como monoterapia o en combinación con otros fármacos, versus placebo o ningún tratamiento en pacientes con sospecha o confirmación de COVID-19. Se buscó identificar experimentos clínicos aleatorizados que evaluaran macrólidos en infecciones causadas por otros coronavirus, como MERS-CoV y SARS-CoV. Dos revisores examinaron de forma independiente la elegibilidad de cada estudio, extrajeron los datos y evaluaron el riesgo de sesgo. Se evaluó el efecto de los macrólidos sobre la mortalidad por todas las causas; necesidad de ventilación mecánica invasiva; oxigenación por membrana extracorpórea, duración de la estancia hospitalaria, insuficiencia respiratoria, eventos adversos graves, tiempo hasta la negatividad de la RT-PCR del SARS-CoV-2. La certeza de la evidencia para cada desenlace se evaluó siguiendo la aproximación GRADE. Esta revisión se mantendrá viva y disponible abiertamente durante la pandemia de COVID-19. Se someterán actualizaciones de su publicación cada vez que cambien las conclusiones o cuando haya actualizaciones sustanciales. RESULTADOS: Se identificó un experimento clínico aleatorio que evaluó el uso de azitromicina en combinación con hidroxicloroquina en comparación con el uso de hidroxicloroquina sola, en pacientes hospitalizados por COVID 19. Las estimaciones para todos los resultados evaluados resultaron en un poder estadístico insuficiente para llegar a conclusiones válidas. La calidad de la evidencia para los resultados principales fue baja a muy baja. CONCLUSIONES: El uso de macrólidos en el tratamiento de pacientes con COVID 19 no ha mostrado efectos beneficiosos en comparación con el tratamiento estándar. La evidencia para todos los desenlaces no es concluyente. Se necesitan estudios sobre un mayor número de pacientes con COVID 19, para determinar los efectos del uso de macrólidos sobre los desenlaces relacionados con la enfermedad.


OBJECTIVE This living, systematic review aims to provide a timely, rigorous, and continuously updated summary of the evidence available on the role of macrolides for treating patients with COVID-19. DESIGN: a living, systematic review. DATABASE: We conducted searches in the centralized repository L·OVE (Living OVerview of Evidence). L·OVE is a platform that maps PICO questions to evidence from the Epistemonikos database. In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it covers and customized to group all COVID-19 evidence in one place. Today it is maintained through regular searches in 39 databases.METHODS: We included randomized trials evaluating the effect of macrolides ­ as monotherapy or in combination with other drugs ­ versus placebo or no treatment in patients with COVID-19. Randomized trials evaluating macrolides in infections caused by other coronaviruses, such as MERS-CoV and SARS-CoV, and non-randomized studies in COVID-19 were searched in case we found no direct evidence from randomized trials. Two reviewers independently screened each study for eligibility, extracted data, and assessed the risk of bias. Measures included all-cause mortality; the need for invasive mechanical ventilation; extracorporeal membrane oxygenation, length of hospital stay, respiratory failure, serious adverse events, time to SARS-CoV-2 RT-PCR negativity. We applied the GRADE approach to assess the certainty of the evidence for each outcome. A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit it every time the conclusions change or whenever there are substantial updates. RESULTS: The search in the L·OVE platform retrieved 424 references. We considered 260 as potentially eligible and were reviewed in full texts. We included one randomized clinical trial that evaluated the use of azithromycin in combination with hydroxychloroquine compared to hydroxychloroquine alone in hospitalized patients with COVID 19. The estimates for all outcomes evaluated resulted in insufficient power to draw conclusions. The quality of the evidence for the main outcomes was low to very low. CONCLUSIONS: Macrolides in the management of patients with COVID 19 showed no beneficial effects compared to standard of care. The evidence for all outcomes is inconclusive. Larger trials are needed to determine the effects of macrolides on pulmonary and other outcomes in COVID-19 patients.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Macrolides/therapeutic use , Pneumonia, Viral/mortality , Respiration, Artificial/statistics & numerical data , Randomized Controlled Trials as Topic , Treatment Outcome , Coronavirus Infections/mortality , Betacoronavirus/isolation & purification
4.
Medwave ; 20(8): e8027, 2020.
Article in English, Spanish | LILACS | ID: biblio-1128722

ABSTRACT

INTRODUCCIÓN: Las revisiones Cochrane, reconocidas como el punto de referencia para resúmenes de alta calidad, facilitan la toma de decisiones en atención médica reuniendo toda la evidencia disponible sobre una intervención. Hasta la fecha, se desconoce su inclusión en las guías latinoamericanas. OBJETTIVO: Evaluar el uso de revisiones Cochrane en guías de práctica clínica desarrolladas a nivel nacional en América Latina. Métodos: Realizamos una búsqueda manual en sitios web oficiales del gobierno y bases de datos biomédicas entre octubre y diciembre de 2019, incluyendo guías de práctica clínica patrocinadas por los gobiernos nacionales con recomendaciones tanto para el manejo de condiciones de salud como para un estilo de vida saludable de los últimos diez años. RESULTADOS: Se incluyeron 408 guías de práctica clínica de diez países. Encontramos que 69,8% de ellas citó revisiones Cochrane en sus recomendaciones y 76,1% de ellas también las utilizó en sus recomendaciones clave. Las guías de práctica clínica que no utilizaron revisiones Cochrane cubrieron una amplia gama de temas, para los cuales se pueden encontrar varias revisiones Cochrane. Los países que utilizan el enfoque Grading of Recommendations, Assessment, Development and Evaluation (GRADE), tenían más probabilidades de utilizar las revisiones Cochrane en un porcentaje más alto de sus guías (79,4% frente a 61,8%; odds ratio: 2,3; intervalo de confianza del 95%: 1,5 a 3,7, p = 0,0001). CONCLUSIONES: Más de dos tercios de las guías de práctica clínica en América Latina utilizan revisiones Cochrane para enmarcar sus recomendaciones. Es necesario incrementar el uso de las revisiones Cochrane en la región para el desarrollo de guías de práctica clínica.


INTRODUCTION: Cochrane reviews, recognized as the benchmark for high-quality summaries, facilitates healthcare decision-making bringing together all the evidence on an intervention. To date, their inclusion in the Latin American guidelines remains unknown. OBJECTIVE: To evaluate the use of Cochrane reviews in nationally-developed clinical practice guidelines in Latin America. METHODS: We conducted a hand search in official government websites and biomedical databases between October 2019 and December 2019, including government-sponsored clinical practice guidelines with recommendations for both the management of health conditions or a healthy lifestyle of the last ten years. RESULTS: We included 408 clinical practice guidelines from ten countries. We found that 69.8% of them cited Cochrane reviews in their recommendations, and 76.1% of those also used them in their key recommendations. Clinical practice guidelines that did not use Cochrane reviews covered a wide range of topics for which several Cochrane reviews can be found. Countries using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach for grading recommendations were more likely to use Cochrane reviews in a higher percentage of their guidelines (79.4% vs. 61.8%; odds ratio: 2.3; 95% confidence interval: 1.5 to 3.7, p = 0.0001). CONCLUSIONS: Over two-thirds of clinical practice guidelines in Latin America use Cochrane reviews to frame their recommendations. It is necessary to increase the uptake of Cochrane reviews in the region for the development of clinical practice guidelines.


Subject(s)
Humans , Review Literature as Topic , Practice Guidelines as Topic , Latin America
5.
Rev. ANACEM (Impresa) ; 14(2): 50-55, 2020.
Article in Spanish | LILACS | ID: biblio-1179928

ABSTRACT

OBJETIVO: Determinar tasa de conversión de colecistectomía laparoscópica, y su distribución por edad, sexo, y comorbilidades. Materiales y método: Estudio descriptivo de corte transversal. Se seleccionó pacientes sobre 50 años que requirieron colecistectomía laparoscópica. Fue determinado el porcentaje de conversión general y por grupo etario. Finalmente se calculó el porcentaje de conversiones según sexo, patologías asociadas y carácter de la cirugía. Resultados: De 175 colecistectomías, 17 (9,1%) requirieron conversión. También se determinó que a mayor edad, mayor tasa de conversión. Pacientes femeninas presentaron menor tasa de conversión que masculinos. Discusión: Los resultados demuestran tasa de conversión baja en comparación con lo expuesto por la literatura. Sexo masculino, edad extrema y presencia de complicaciones son posiblemente de mayor riesgo. Creemos relevante realizar más estudios, ahondando en la evolución postoperatoria.


OBJETIVE: Establish conversion rates of laparoscopic cholecystectomy, and its distribution by age, sex, and comorbidities. Materials and Method: Descriptive cross-sectional study. We selected patients over 50 years old, who needed laparoscopic cholecystectomy. Rates of conversion were determined. Finally, the proportions according to sex, associated pathologies and urgency of the surgery were determined. Results: From 175 cholecystectomies, 17 (9,1%) needed conversion. It was also determined that higher age relates to higher conversion rate. Female patients had lower conversion rate than males. Discussion: The results obtained, show low conversion rates comparing with those featured in literature. Males, extreme ages and presence of complications are possibly at greater risk. We believe it's important to perform more studies involving postoperative evolution


Subject(s)
Humans , Male , Female , Middle Aged , Cholecystectomy/statistics & numerical data , Cholecystectomy, Laparoscopic , Conversion to Open Surgery/statistics & numerical data , Epidemiology, Descriptive , Cross-Sectional Studies , Retrospective Studies , Laparoscopy , Hospitals
6.
Rev. méd. Chile ; 144(5): 626-633, mayo 2016. ilus, tab
Article in Spanish | LILACS | ID: lil-791051

ABSTRACT

There is strong evidence about the co-existence of body dysmorphic disorder (BDD) and eating disorders (ED), particularly with anorexia nervosa (AN). An exhaustive review of the specialised literature regarding these disorders was carried out. The results show that their co-occurrence implies a more complex diagnosis and treatment, a more severe clinical symptomatology and a worse prognosis and outcome. Both disorders display common similarities, differences and comorbidities, which allow authors to classify them in different nosological spectra (somatomorphic, anxious, obsessive-compulsive, affective and psychotic). Their crossover involves higher levels of body dissatisfaction and body image distortion, depression, suicidal tendency, personality disorders, substance use/abuse, obsessive-compulsive disorder, social phobia, alexithymia and childhood abuse or neglect background. Treatment including cognitive-behavioral psychotherapy and selective reuptake serotonin inhibitors are effective for both, BDD and ED; nevertheless, plastic surgery could exacerbate BDD. Clinical traits of BDD must be systematically detected in patients suffering from ED and vice versa.


Subject(s)
Humans , Anorexia Nervosa/psychology , Body Dysmorphic Disorders/psychology , Antipsychotic Agents , Anti-Anxiety Agents , Anorexia Nervosa/therapy , Cognitive Behavioral Therapy , Comorbidity , Selective Serotonin Reuptake Inhibitors , Body Dysmorphic Disorders/therapy , Antidepressive Agents
SELECTION OF CITATIONS
SEARCH DETAIL